Zhenzhun Biotech

Zhenzhun Biotech, officially named Zhenzhun Biotechnology (Shanghai) Co. Ltd., is a life sciences company established in 2016 and based in Shanghai, China. The firm concentrates on the development, production, and sales of diagnostic medical devices, consumables, and reagents, with a specific focus on micro-chip-based digital PCR (Polymerase Chain Reaction) technology. The company's team possesses extensive experience from well-known multinational corporations and research institutions in fields such as micro and nano processing, precision instruments, and biological reagents.

The core of Zhenzhun Biotech's business is its digital PCR platform, which offers a significant advancement over traditional real-time fluorescence PCR. This technology allows for the absolute quantification of nucleic acid copy numbers with a high detection sensitivity of up to 0.01%, presenting broad application prospects in life sciences and clinical diagnostics. The company has developed its own chip-based digital PCR instruments, such as the AccuONE series, and accompanying analysis software. By focusing on the "micro-chip" technical route, which is noted for its homogeneity, stability, and efficiency, Zhenzhun Biotech has positioned itself in alignment with the direction taken by international industry leaders. Their product line includes various digital PCR Mix kits for both dye-based and probe-based methods.

Since its founding, Zhenzhun Biotech has achieved several key milestones, including the successful development of its AccuONE-100 dPCR system in 2018 and the AccuONE-200 in 2020. A significant achievement came in March 2022, when the company secured over CNY 100 million in a Series A financing round, exclusively invested by Huiyuan Capital. This funding was designated for the clinical registration, marketing, and production scale-up of its microchip-based digital PCR products and the development of multiple diagnostic kits. The company's development timeline also includes the completion of its production line in 2021 and the successful development of its AccuMini series dPCR and an all-in-one dPCR machine in 2022 and 2023, respectively.

Keywords: digital PCR, micro-chip technology, molecular diagnostics, life sciences, diagnostic devices, nucleic acid quantification, precision medicine, in-vitro diagnostics, biotechnology, gene detection, medical consumables, clinical diagnostics, PCR analysis software, absolute quantification, liquid biopsy, cancer detection, infectious disease testing, genetic analysis, molecular biology, diagnostic reagents